{"id":265313,"date":"2026-02-03T09:52:07","date_gmt":"2026-02-03T09:52:07","guid":{"rendered":"https:\/\/www.newsbeep.com\/nz\/265313\/"},"modified":"2026-02-03T09:52:07","modified_gmt":"2026-02-03T09:52:07","slug":"pharmac-urged-to-fund-weight-loss-drug-for-teens","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/nz\/265313\/","title":{"rendered":"Pharmac urged to fund weight loss drug for teens"},"content":{"rendered":"<p>A paediatric specialist is urging New Zealand&#8217;s drug funding agency to fund weight loss medication for teenagers.<\/p>\n<p>A Pharmac advisory panel has\u00a0provisionally recommended funding Wegovy\u00a0for chronic weight management in people with high BMI&#8217;s and associated conditions.<\/p>\n<p>The semaglutide drug first became available here in July last year, and currently costs about $460 a month.<\/p>\n<p>The advisory group&#8217;s recommendation is subject to Special Authority criteria, which will limit who can prescribe it.<\/p>\n<p>The recommendation has been announced after the advisory group met in December, with a full record of the meeting expected to be available by March.<\/p>\n<p>But one specialist believes there are a number of teenagers who would benefit from the drug if it is funded.<\/p>\n<p>Professor Wayne Cutfield, a professor of paediatric endocrinology at the Liggins Institute, told RNZ&#8217;s Checkpoint programme today that funding Wegovy for teens would help prevent serious health issues before they arose.<\/p>\n<p>He said he frequently sees very obese teenagers coming into the clinic.<\/p>\n<p>&#8220;These are teenagers who weigh between 120 and 150 kilograms &#8211; these are 14- to 16-year-old teenagers.&#8221;<\/p>\n<p>&#8220;Most of these teenagers who have severe obesity will gain between half a kilogram and a kilogram a month &#8211; month on month, year on year&#8230; you can see by the time they&#8217;re 45, they will have much more severe obesity.&#8221;<\/p>\n<p>Cutfield said Pharmac choosing not to fund the drug for teenagers would be like &#8220;closing the gate after the horse had bolted.<\/p>\n<p>&#8220;Do they want to try and stop them from having heart attacks, stop them from having strokes, stop them from developing rampant diabetes or liver disease leading to sclerosis?&#8221;<\/p>\n<p>Real-world follow-ups of patients who have taken Wegovy have shown that weight regain can happen quickly after stopping the drug.<\/p>\n<p>&#8220;There is often a return back to the pre-treatment weight. And the reason is, Wegovy suppresses appetite.&#8221;<\/p>\n<p>Cutfield said that lifestyle changes were incredibly important to sustain weight loss and prevent teens from being on the drug for a lifetime<\/p>\n<p>&#8220;Unless patients taking Wegovy make lifestyle changes, in other words, learn to diet, learn to eat less, and be more active they are going to be on treatment potentially lifelong.&#8221;<\/p>\n<p>Pharmac has not yet signalled whether teens will be eligible for the drug if it is funded, however Cutfield believes it is highly likely this will be the case.<\/p>\n<p>&#8220;If you look at any form of obesity treatment at the moment, these very obese teenagers are not eligible for bariatric surgery, there&#8217;s kind of nothing for them. Unless they get included, they are simply going to wait and get larger and larger and start developing obesity-related complications.&#8221;<\/p>\n<p>At the cost of around $460 a month, Cutfield said there is very much so an &#8220;equity issue&#8221; surrounding access to Wegovy.<\/p>\n<p>He said the cost benefit of funding the drug are &#8220;potentially enormous&#8221;.<\/p>\n<p>&#8220;You&#8217;re preventing serious diseases for which there are huge costs in terms of treatment costs, hospitalisations, lost time off work, chronic ill- health, diabetes, heart attacks, strokes, severe liver disease, obstructive sleep apnea, affecting your capacity to breathe at night.&#8221;<\/p>\n<p>However, Cutfield said health practitioners should have a stronger focus on implementing lifestyle changes for patients alongside prescribing the drug.<\/p>\n<p>&#8220;I think as medical practitioners, and those who take the drug, we&#8217;ve got to collectively work harder at getting patients eventually off the drug and not have them on this drug for life.&#8221;<\/p>\n<p>Pharmac&#8217;s director device and assessment Dr David Hughes told\u00a0Checkpoint\u00a0that Pharmac recently released the provisional recommendation from its Obesity Treatments Advisory Group in regards to current funding applications for Semaglutide (Wegovy).<\/p>\n<p>&#8220;Typically, unless there is a strong clinical rationale or evidence for doing so, the age of individuals is not one of the factors Pharmac considers when making funding decisions.&#8221;<\/p>\n<p>He said the full record of the recommendations related to these applications is expected to be released in full in March 2026.<\/p>\n<p>Previously, Pharmac had received two applications to fund Wegovy.<\/p>\n<p>The first was in September, for people with an established cardiovascular disease (such as someone who has had a heart attack or stroke) and a BMI of 27 or higher. The second was in October, for chronic weight management in people with a BMI of 30 or higher, with at least one weight-related comorbidity.<\/p>\n<p>New Zealand has the third-highest adult obesity rate in the Organisation for Economic Co-operation and Development (OECD).<\/p>\n","protected":false},"excerpt":{"rendered":"A paediatric specialist is urging New Zealand&#8217;s drug funding agency to fund weight loss medication for teenagers. A&hellip;\n","protected":false},"author":2,"featured_media":265314,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[33],"tags":[134,524,111,139,69],"class_list":["post-265313","post","type-post","status-publish","format-standard","has-post-thumbnail","category-medication","tag-health","tag-medication","tag-new-zealand","tag-newzealand","tag-nz"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/posts\/265313","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/comments?post=265313"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/posts\/265313\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/media\/265314"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/media?parent=265313"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/categories?post=265313"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/tags?post=265313"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}